Navigation Links
MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
Date:1/15/2014

tives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
2. MultiCell Announces Results of Shareholders Meeting
3. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
4. MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
9. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 BioDelivery Sciences International, Inc. ... Board of Directors has appointed Charles J. (Chuck) ... as members of the Board.  Mr. ... experience in marketing, sales and other commercial functions.  He ... Inc., a development stage company that was recently acquired ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ™ ... neuropsychiatric disorders, today announced that enrollment has begun in ... stimulation (eTNS) as adjunctive therapy for the treatment of ... conducted at the Olive View-UCLA Medical Center in ...
(Date:7/21/2014)... ANGELES , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, ... oxide supplements , will celebrate its first anniversary in ... that is designed to enhance the body,s ability to ... formula that is made up of a variety of ... said have been found to increase nitric oxide ...
Breaking Medicine Technology:BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/22/2014)... July 22, 2014 Dimension One Spas’ ... 24 months on all models during the “Let’s Take ... Please visit http://www.d1spas.com/financing for more information and ... Dimension One Spas offers a wide variety of outdoor ... lights, fountains, waterfalls, music, customizable massage, and personal controls. ...
(Date:7/22/2014)... July 22, 2014 Over the ... almost every sphere of human anatomy. In the ... advancements that rendered the possibility of deploying certain ... blood and tissues, in order to detect the ... abnormality. Essentially, In-vitro Diagnostics (IVD) have earned the ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Simple blood tests may one day help predict survival and ... sclerosis (ALS), also called Lou Gehrig,s disease, Italian researchers report. ... clues to how fast ALS is progressing are called albumin ... and liver health, according to the U.S. National Library of ...
(Date:7/22/2014)... of coffee and sit down to read People magazine. How ... you reach for another cup? Would you need more caffeine ... study in the Journal of Consumer Research finds ... and aspirin lose their effectiveness when they engage in more ... it takes for products to wear off. For example, they ...
(Date:7/22/2014)... an astronaut is a much-studied thing. Scientists have analyzed ... even matters of the heart. But for the first ... inflammation caused by the conditions of space flight affect ... fly on the International Space Station. Lessons learned may ... Oxidative stress reflects an imbalance in the body,s ability ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:Why do challenging tasks make consumers believe drugs wear off faster? 2Health News:The heart of an astronaut, five years on 2Health News:The heart of an astronaut, five years on 3
... ... Foundation has teamed up with Pilot Pen to create a line of ... Breast Cancer Foundation is a nonprofit committed to providing direct financial assistance ... early detection and survival of breast cancer. To show support Pilot Pen ...
... ... Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the release of ... ... -- Purity Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the ...
... Research suggests millions are going without needed medical services , ... a history of cancer, particularly people under age 65, are ... the cost of treatment, a new study suggests. , ... quality of life of the 12 million adults in the ...
... ... with the modern and hits big on iTunes store first days of launch , ... New York, NY (PRWEB) June 14, 2010 -- 2010 ... “The Karate Kid”, two events bringing renewed popular interest in Chinese martial arts. , , , ...
... ... of the dangers of cycling injuries and urges caution on the roads , ... (PRWEB) June 14, 2010 -- National Accident Helpline is urging ... weather is seeing an increasing number of people take to their bikes, often for the first ...
... ... production assets, inventory and certain information of the Cell-Pore product group previously owned and ... ... today that it has completed its purchase of the principal manufacturing and production assets, ...
Cached Medicine News:Health News:The American Breast Cancer Foundation Partners with Pilot Pen to Raise Breast Cancer Awareness Nation-Wide 2Health News:The American Breast Cancer Foundation Partners with Pilot Pen to Raise Breast Cancer Awareness Nation-Wide 3Health News:Purity Products Releases Ultimate Sleep Plus Melatonin 2Health News:Cost-Conscious Cancer Survivors Skip Care 2Health News:Cost-Conscious Cancer Survivors Skip Care 3Health News:New iPhone App “Wing Chun Masters” Brings 400-Year-Old Kung Fu To Life Amidst Renewed Popular Interest In Culture. 2Health News:New iPhone App “Wing Chun Masters” Brings 400-Year-Old Kung Fu To Life Amidst Renewed Popular Interest In Culture. 3Health News:Break The Injury Cycle, Says National Accident Helpline 2Health News:CerMedia Completes Purchase of Cell-Pore Principal Assets from NanoDynamics 2